La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Firebrick Pharma Dividendo

Dividendo criteri di controllo 0/6

Firebrick Pharma does not have a record of paying a dividend.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.1%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-AU$0.023
Previsione del rendimento del dividendo a 3 anni	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Insufficient data to determine if FRE's dividends per share have been stable in the past.

Dividendo in crescita: Insufficient data to determine if FRE's dividend payments have been increasing.

Rendimento dei dividendi rispetto al mercato

Firebrick Pharma Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di FRE rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (FRE)	n/a
Fondo del 25% del mercato (AU)	2.6%
Top 25% del mercato (AU)	6.1%
Media del settore (Pharmaceuticals)	2.1%
Previsione dell'analista in 3 anni (FRE)	n/a

Dividendo notevole: Unable to evaluate FRE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividendo elevato: Unable to evaluate FRE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Distribuzione degli utili agli azionisti

Copertura degli utili: Insufficient data to calculate FRE's payout ratio to determine if its dividend payments are covered by earnings.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Unable to calculate sustainability of dividends as FRE has not reported any payouts.

Firebrick Pharma Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.8 million.

New minor risk - Share price stability

Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common Cold

Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)

Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation

Firebrick Update on Administrative Appeals Tribunal Process

Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023

We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully

We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully

No independent directors

Firebrick Pharma Limited Announces CFO Changes

Firebrick Pharma Limited Provides Update on its Phase 3 Clinical Trial of Nasodine Nasal Spray in Treatment of Common Cold

Rebrick Pharma Limited Announces Nasodine Patent Granted in Singapore

Firebrick Pharma Limited, Annual General Meeting, Nov 23, 2022

Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth

Firebrick Appoints Richard Treagus as Director

Firebrick Appoints Richard Treagus as Director

Firebrick Pharma Limited Starts Phase 3 Common Cold Trial

No independent directors

Firebrick Pharma Limited Starts COVID-19 Trial of Nasodine

Firebrick Pharma Limited Announces the Results of in Vitro Studies of Nasodine® Nasal Spray

Firebrick Pharma Limited Announces That Its Planned Clinical Trial of Nasodine Nasal Spray (Povidone-Iodine 0.5%) in Covid-19 Patients in South Africa, Had Received Approval to Proceed from the South African Health Products Regulatory Authority

No independent directors

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti